Poseida Therapeutics, Inc.
PSTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $303 | $381 | $423 | $641 |
| - Cash | $44 | $81 | $206 | $84 |
| + Debt | $85 | $89 | $61 | $59 |
| Enterprise Value | $344 | $389 | $278 | $616 |
| Revenue | $65 | $130 | $0 | $0 |
| % Growth | -50.4% | 417,217.1% | – | – |
| Gross Profit | -$92 | $125 | -$5 | -$3 |
| % Margin | -142.3% | 96% | -14,472% | – |
| EBITDA | -$109 | -$52 | -$117 | -$145 |
| % Margin | -168.5% | -39.8% | -374,748.7% | – |
| Net Income | -$123 | -$64 | $4 | $2 |
| % Margin | -190.8% | -49.1% | 14,097.8% | – |
| EPS Diluted | -1.37 | -0.89 | 0.071 | 0.042 |
| % Growth | -53.9% | -1,357.1% | 68.6% | – |
| Operating Cash Flow | -$92 | -$27 | -$103 | -$113 |
| Capital Expenditures | -$3 | -$4 | -$3 | -$17 |
| Free Cash Flow | -$95 | -$31 | -$105 | -$130 |